The historical rank and industry rank for 4D Molecular Therapeutics's Net Margin % or its related term are showing as below:
FDMT'
s Net Margin % Range Over the Past 10 Years
Min: -434778.38 Med: -416.49 Max: -67.59
Current: -182.34
FDMT's Net Margin % is ranked worse than 59.24% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs FDMT: -182.34
4D Molecular Therapeutics (NAS:FDMT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
4D Molecular Therapeutics Net Margin % Related Terms
4D Molecular Therapeutics Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 4D Molecular Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics (FDMT) has a Net Margin % of -2,256.65% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on 4D Molecular Therapeutics and its competitors. According to the industry distribution chart, 4D Molecular Therapeutics ranks #561 out of 947 companies in the Biotechnology industry, placing it in the top 59.2%.
Is 4D Molecular Therapeutics' Net Margin % too high?
4D Molecular Therapeutics' current Net Margin % is -2,256.65%. Based on the distribution chart, 4D Molecular Therapeutics ranks #561 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Net Margin % compare to KYTX and XOMA?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #561 out of 947 companies for Net Margin %. This places 4D Molecular Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Net Margin % is -2,256.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.38, compared to a current price of $11.50 — trading 94.6% below its estimated fair value. The current Net Margin % is -2,256.65%. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Net Margin % is -2,256.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $11.50 is trading 94.6% below its estimated GF Value™ of $214.38.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
Net Margin %: -2,256.65%
GF Value™: $214.38 vs. price of $11.50 (94.6% below fair value)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score
Get the complete analysis for FDMT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
